PMID- 31108276
OWN - NLM
STAT- MEDLINE
DCOM- 20200410
LR  - 20200410
IS  - 1879-0887 (Electronic)
IS  - 0167-8140 (Linking)
VI  - 137
DP  - 2019 Aug
TI  - Boron neutron capture therapy for locally recurrent head and neck squamous cell 
      carcinoma: An analysis of dose response and survival.
PG  - 153-158
LID - S0167-8140(19)30396-2 [pii]
LID - 10.1016/j.radonc.2019.04.033 [doi]
AB  - BACKGROUND AND PURPOSE: Head and neck squamous cell carcinoma (HNSCC) that recurs 
      locally is a therapeutic challenge. We investigated the efficacy of boron neutron 
      capture therapy (BNCT) in the treatment of such patients and the factors 
      associated with treatment response and survival. METHODS AND MATERIALS: 
      Seventy-nine patients with inoperable, locally recurred HNSCC were treated with 
      l-boronophenylalanine-mediated BNCT in Espoo, Finland, between February, 2003 and 
      January, 2012. Prior treatments consisted of surgery and conventionally 
      fractionated radiotherapy to a median cumulative dose of 66 Gy (interquartile 
      range [IQR], 59-70 Gy) administered with or without concomitant chemotherapy. 
      Tumor response was assessed using the RECISTv.1.0 criteria. RESULTS: Forty 
      patients received BNCT once (on 1 day), and 39 twice. The median time between the 
      2 treatments was 6 weeks. Forty-seven (68%; 95% confidence interval [CI], 57-79%) 
      of the 69 evaluable patients responded; 25 (36%) had a complete response, 22 
      (32%) a partial response, 17 (25%) a stable disease lasting for a median of 
      4.2 months, and 5 (7%) progressed. The patients treated with BNCT twice responded 
      more often than those treated once. The median follow-up time after BNCT was 
      7.8 years. The 2-year locoregional progression-free survival rate was 38% and the 
      overall survival rate 21%. A high minimum tumor dose and a small volume were 
      independently associated with long survival in a multivariable analysis. 
      CONCLUSIONS: Most patients responded to BNCT. A high minimum tumor dose from BNCT 
      was predictive for response and survival.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Koivunoro, Hanna
AU  - Koivunoro H
AD  - Department of Oncology, Helsinki University Hospital and University of Helsinki, 
      Finland; Neutron Therapeutics Finland Ltd, Helsinki, Finland.
FAU - Kankaanranta, Leena
AU  - Kankaanranta L
AD  - Department of Oncology, Helsinki University Hospital and University of Helsinki, 
      Finland.
FAU - Seppala, Tiina
AU  - Seppala T
AD  - Department of Oncology, Helsinki University Hospital and University of Helsinki, 
      Finland.
FAU - Haapaniemi, Aaro
AU  - Haapaniemi A
AD  - Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki University 
      Hospital and University of Helsinki, Finland.
FAU - Makitie, Antti
AU  - Makitie A
AD  - Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki University 
      Hospital and University of Helsinki, Finland.
FAU - Joensuu, Heikki
AU  - Joensuu H
AD  - Department of Oncology, Helsinki University Hospital and University of Helsinki, 
      Finland. Electronic address: heikki.joensuu@hus.fi.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190517
PL  - Ireland
TA  - Radiother Oncol
JT  - Radiotherapy and oncology : journal of the European Society for Therapeutic 
      Radiology and Oncology
JID - 8407192
SB  - IM
MH  - Aged
MH  - Boron Neutron Capture Therapy/*methods
MH  - Female
MH  - Head and Neck Neoplasms/*radiotherapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*radiotherapy
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Squamous Cell Carcinoma of Head and Neck/*radiotherapy
MH  - Survival Rate
OTO - NOTNLM
OT  - Boron neutron capture therapy
OT  - Boronophenylalanine
OT  - Head and neck cancer
OT  - Radiotherapy
EDAT- 2019/05/21 06:00
MHDA- 2020/04/11 06:00
CRDT- 2019/05/21 06:00
PHST- 2018/08/11 00:00 [received]
PHST- 2019/03/03 00:00 [revised]
PHST- 2019/04/29 00:00 [accepted]
PHST- 2019/05/21 06:00 [pubmed]
PHST- 2020/04/11 06:00 [medline]
PHST- 2019/05/21 06:00 [entrez]
AID - S0167-8140(19)30396-2 [pii]
AID - 10.1016/j.radonc.2019.04.033 [doi]
PST - ppublish
SO  - Radiother Oncol. 2019 Aug;137:153-158. doi: 10.1016/j.radonc.2019.04.033. Epub 
      2019 May 17.